Arax Advisory Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Arax Advisory Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71.1K	Sell	242 -348	-59%	-$98.7K	﹤0.01%	2988
2026 Q1	$163K	Sell	590 -152	-20%	-$43.8K	﹤0.01%	1174
2025 Q4	$225K	Sell	742 -1,328	-64%	-$414K	0.01%	986
2025 Q3	$580K	Buy	2,070 +1,933	+1,411%	+$526K	0.01%	851
2025 Q2	$33.1K	Buy	137 +22	+19%	+$5.2K	﹤0.01%	1433
2025 Q1	$28K	Buy	115 +92	+400%	+$27.7K	﹤0.01%	1162
2024 Q4	$7.56K	Buy	+23	New	+$7.81K	﹤0.01%	1587
2024 Q2	–	Sell	-3	Closed	-$1.04K	–	2547
2024 Q1	$1.04K	Buy	+3	New	+$987	﹤0.01%	1148
2023 Q2	–	Sell	-7	Closed	-$3.35K	–	1273
2023 Q1	$3.35K	Hold	7	–	–	﹤0.01%	927
2022 Q4	$2.94K	Buy	+7	New	+$2.83K	﹤0.01%	901
2021 Q3	–	Sell	-10	Closed	-$6K	–	996
2021 Q2	$6K	Buy	+10	New	+$6.09K	﹤0.01%	731

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Arax Advisory Partners's BIO Position: Q2 2026 in Review

Arax Advisory Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 59% in Q2 2026, selling an estimated $98.7K and leaving 242 shares worth $71.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2988.

Arax Advisory Partners first reported a position in BIO in Q2 2021 and has held it in 11 quarters since. The position peaked at $580K in Q3 2025. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Arax Advisory Partners held 242 shares of Bio-Rad Laboratories Class A worth $71.1K as of Q2 2026.
Arax Advisory Partners sold 348 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $98.7K.
Bio-Rad Laboratories Class A made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2988 holding.
Arax Advisory Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and has held it in 11 quarters since.
Arax Advisory Partners's Bio-Rad Laboratories Class A position peaked at $580K in Q3 2025.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.